KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biomarin Pharmaceutical (BMRN) EBIT (2017 - 2025)

Biomarin Pharmaceutical (BMRN) has disclosed EBIT for 16 consecutive years, with -$44.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBIT fell 127.64% year-over-year to -$44.6 million, compared with a TTM value of $409.5 million through Dec 2025, down 15.43%, and an annual FY2025 reading of $409.5 million, down 15.43% over the prior year.
  • EBIT was -$44.6 million for Q4 2025 at Biomarin Pharmaceutical, up from -$46.7 million in the prior quarter.
  • Across five years, EBIT topped out at $276.9 million in Q2 2025 and bottomed at -$65.9 million in Q4 2021.
  • Average EBIT over 5 years is $58.6 million, with a median of $40.5 million recorded in 2022.
  • The sharpest move saw EBIT soared 1362.93% in 2023, then plummeted 141.0% in 2025.
  • Year by year, EBIT stood at -$65.9 million in 2021, then soared by 80.13% to -$13.1 million in 2022, then surged by 420.11% to $41.9 million in 2023, then skyrocketed by 285.26% to $161.4 million in 2024, then tumbled by 127.64% to -$44.6 million in 2025.
  • Business Quant data shows EBIT for BMRN at -$44.6 million in Q4 2025, -$46.7 million in Q3 2025, and $276.9 million in Q2 2025.